<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965792</url>
  </required_header>
  <id_info>
    <org_study_id>20-340</org_study_id>
    <nct_id>NCT04965792</nct_id>
  </id_info>
  <brief_title>Post-treatment Surveillance in HPV+ Oropharyngeal SCC</brief_title>
  <official_title>Circulating HPV DNA for Post-treatment Surveillance in HPV-positive Oropharyngeal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study the investigators are examining a blood test to detect HPV DNA in the&#xD;
      blood that can possibly detect cancer recurrence earlier than with standard surveillance&#xD;
      measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study involves blood tests to detect HPV DNA at regular time points after&#xD;
      treatment for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Participants may&#xD;
      undergo scans based on the results of the blood tests. Study participants will also be asked&#xD;
      to complete quality of life questionnaires periodically.&#xD;
&#xD;
      Participation in this study may last for up to 5 years. It is expected that about 150 people&#xD;
      will take part in this research study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent disease Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The proportion of patients with recurrence first detected by ctHPV DNA will be calculated as a percentage and 95% confidence intervals (CI) established using binomial exact calculation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Detection Predictive Properties</measure>
    <time_frame>Time from first positive ctHPV DNA test to diagnosis of recurrence, assessed up to 5 years</time_frame>
    <description>Estimate positive and negative predictive value, sensitivity and specificity of ctHPV DNA for subsequent diagnosis of recurrent HPV-OPC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis of recurrence</measure>
    <time_frame>Time from first positive ctHPV DNA test to confirmed diagnosis of recurrence, assessed up to 5 years</time_frame>
    <description>The median (IQR) number of months between the first positive ctHPV DNA test to definitive diagnosis of recurrence will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Time from registration to the earlier of progression or death due to any cause, assessed up to 5 years</time_frame>
    <description>Calculated using Kaplan Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time from registration to death due to any cause, or censored at date last known alive, assessed up to 5 years</time_frame>
    <description>Calculated using Kaplan Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>Pre-study, at 3 and 6 months, then at every other visit for the duration of the study up to 5 years</time_frame>
    <description>QOL will be evaluated using the by Fear of Recurrence Questionnaire-Short Form (score range 6-40; lower score is lower fear of recurrence) and EQ-5D-5L questionnaire (5 questions with score range 1-5 where higher score is worse; and one question with score range 0-100 where higher is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Comparison</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Projected cost of ctHPV DNA-based compared with standard surveillance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HPV</condition>
  <condition>Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients</arm_group_label>
    <description>Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening</intervention_name>
    <description>Blood test</description>
    <arm_group_label>HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Must have&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have histologically or cytologically confirmed incident or recurrent&#xD;
             squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes biopsy&#xD;
             of any lymph node with clinical evidence of an oropharynx tumor (unknown primary&#xD;
             carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV&#xD;
             testing is positive on the involved node)&#xD;
&#xD;
          -  HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry&#xD;
             (&gt;70%) OR in situ hybridization OR PCR-based methods&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Will undergo oropharyngeal cancer treatment with curative intent&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Baseline positive or detectable ctHPV DNA result prior to treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastatic disease (M1, AJCC 8th edition)&#xD;
&#xD;
          -  Undetectable ctHPV DNA result at baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni M Rettig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleni M Rettig, MD</last_name>
    <phone>617-632-3643</phone>
    <email>emrettig@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Haddad, MD</last_name>
      <phone>617-632-3779</phone>
      <email>rhaddad@partners.org</email>
    </contact>
    <investigator>
      <last_name>Robert Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Eleni Marie Rettig</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Oropharyngeal Squamous Cell Carcinoma</keyword>
  <keyword>HPV + Oropharyngeal Squamous Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

